Technical analysis is a method used by traders and investors to evaluate the price movement and trends of a particular stock or financial instrument. It involves analyzing various technical indicators and using mathematical calculations to identify potential buying or selling opportunities. In the case of Beam Therapeutics Inc (BEAM), several technical indicators can be used to assess the stock's performance.

One commonly used technical indicator is the Relative Strength Index (RSI), which measures the speed and change of price movements. The RSI for BEAM stock can provide insights into whether the stock is overbought or oversold, indicating potential reversals in price. Another useful indicator is the Average Directional Index (ADX), which can help identify the strength of a trend. A high ADX value suggests a strong trend, while a low value indicates a weak trend.

Beam Therapeutics  (BEAM) Technical Analysis

Learn about Beam Therapeutics Inc (BEAM) technical analysis indicators, including RSI, ADX, MACD, ROC, STOCHRSI, and WILLR. Find insights into the stock's trends and performance without using any verbs after full stops. Reportatively explain the analysis in two informative paragraphs.

Beam Therapeutics Inc (BEAM) Technical Analysis: Indicators, RSI, ADX, MACD, ROC, STOCHRSI, WILLR

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 and BEAM-102 for the treatment of sickle cell disease beta thalassemia; BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease; and the Institute of Molecular and Clinical Ophthalmology Basel for treatment of impaired vision and blindness. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Beam Therapeutics 

NASDAQ

This suggests that the technical indicators do not strongly favor either a buying or selling stance. In such cases, investors may need to rely on additional fundamental or market analysis to make a well-informed decision.

Balanced or Uncertain

MACD

WILLR

STOCHRSI

Free

is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.

Name	Value	Action	infoPnL (10y)
auto_graphRSI	68.90	Neutral	19.7%
auto_graphMACD	33.21	Neutral	955.9%
auto_graphCCI	181.61	Sell	261.4%
auto_graphADX	31.96	Neutral	-
auto_graphATR	65.18	Buy	-
auto_graphWILLR	-21.43	Neutral	331.4%
auto_graphROC	132.99	Neutral	609.7%
auto_graphSTOCHRSI	92.29	Sell	103.7%

Buy	1	-87.50%
Hold	5	-37.50%
Sell	2	-75.00%

Trendlines, Support and Resistance

Welcome to Stocklytics

Technical Indicators

Indicator Ratings

Balanced or Uncertain

Beam Therapeutics (BEAM) Technical Analysis

Keep an eye on Beam Therapeutics

Frequently Asked Questions

What are the technical signals for Beam Therapeutics (BEAM) stock based on the last 30 days?

Take Your Investments to a Whole New Level